Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAL0120 in Uncontrolled and Resistant Hypertension
NCT07790120Phase 3Completed
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of SAL0120 in hypertension (HTN) and resistant hypertension (RH) (4 arms), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. Primary endpoint: Change From Baseline in Seated Systolic Blood Pressure at 12 weeks. Started Oct 2024; status: completed.
02
Drugs
SAL0120
03
Conditions
hypertension (HTN)resistant hypertension (RH)
Beyond the preview
Go deeper on NCT07790120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07790120.